BACKGROUND/AIM: Retinoblastoma is the commonest primary intraocular tumour in children. Chemotherapy now plays a big part in the treatment of these tumours. There is not much information about the role of the multidrug resistance proteins (MDR)-P-glycoprotein (P-gp) and vault protein lung resistance protein (LRP)-in retinoblastoma. The authors investigated the expression of P-gp and LRP in retinoblastoma and correlated them clinicopathologically. METHODS: Among 60 retinoblastomas, 40 tumours were not subjected to preoperative or postoperative chemotherapy and 20 tumours were subjected to postoperative chemotherapy. In this cohort 27 tumours had no invasion and 33 tumours had invasion of choroid, optic nerve, and orbit. P-gp and LRP expression were studied by immunohistochemistry. Immunoanalysis was done semiquantitatively. RESULTS: Among the 60 tumours P-gp was expressed in 23 (38%) tumours and LRP was expressed in 35 (58%). P-gp was expressed in 11/27 (40%) tumours with no invasion and in 12/33 (36%) tumours with invasion. LRP was expressed in 15/27 (55%) tumours with no invasion and in 20/33 (60%) tumours with invasion. Both P-gp and LRP were negative in three tumours with invasion, which had later developed bone marrow metastasis. There was no correlation between P-gp and LRP expression with invasion, differentiation and laterality of the tumours and response to treatment. CONCLUSION: Retinoblastoma expresses P-gp and LRP intrinsically before chemotherapy and none of these proteins predicted the response to chemotherapy. Thus, further studies are needed to understand the significance of the expression of the P-gp and LRP proteins in retinoblastoma.
BACKGROUND/AIM: Retinoblastoma is the commonest primary intraocular tumour in children. Chemotherapy now plays a big part in the treatment of these tumours. There is not much information about the role of the multidrug resistance proteins (MDR)-P-glycoprotein (P-gp) and vault protein lung resistance protein (LRP)-in retinoblastoma. The authors investigated the expression of P-gp and LRP in retinoblastoma and correlated them clinicopathologically. METHODS: Among 60 retinoblastomas, 40 tumours were not subjected to preoperative or postoperative chemotherapy and 20 tumours were subjected to postoperative chemotherapy. In this cohort 27 tumours had no invasion and 33 tumours had invasion of choroid, optic nerve, and orbit. P-gp and LRP expression were studied by immunohistochemistry. Immunoanalysis was done semiquantitatively. RESULTS: Among the 60 tumours P-gp was expressed in 23 (38%) tumours and LRP was expressed in 35 (58%). P-gp was expressed in 11/27 (40%) tumours with no invasion and in 12/33 (36%) tumours with invasion. LRP was expressed in 15/27 (55%) tumours with no invasion and in 20/33 (60%) tumours with invasion. Both P-gp and LRP were negative in three tumours with invasion, which had later developed bone marrow metastasis. There was no correlation between P-gp and LRP expression with invasion, differentiation and laterality of the tumours and response to treatment. CONCLUSION:Retinoblastoma expresses P-gp and LRP intrinsically before chemotherapy and none of these proteins predicted the response to chemotherapy. Thus, further studies are needed to understand the significance of the expression of the P-gp and LRP proteins in retinoblastoma.
Authors: D L Friedman; B Himelstein; C L Shields; J A Shields; M Needle; D Miller; G R Bunin; A T Meadows Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: H S Chan; Y Lu; T M Grogan; G Haddad; D R Hipfner; S P Cole; R G Deeley; V Ling; B L Gallie Journal: Cancer Res Date: 1997-06-15 Impact factor: 12.701
Authors: G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper Journal: Nat Med Date: 1995-06 Impact factor: 53.440
Authors: H S Chan; G DeBoer; J J Thiessen; A Budning; J E Kingston; J M O'Brien; G Koren; E Giesbrecht; G Haddad; Z Verjee; J L Hungerford; V Ling; B L Gallie Journal: Clin Cancer Res Date: 1996-09 Impact factor: 12.531
Authors: A J Zurita; J E Diestra; E Condom; X García Del Muro; G L Scheffer; R J Scheper; J Pérez; J R Germà-Lluch; M A Izquierdo Journal: Br J Cancer Date: 2003-03-24 Impact factor: 7.640
Authors: I J Dunkel; D H Abramson; C Cordon-Cardo; G L Chantada; M T G de Davila; A C Fandino Journal: Br J Ophthalmol Date: 2005-06 Impact factor: 4.638
Authors: Carlos Rodriguez-Galindo; Mathew W Wilson; Guillermo Chantada; Ligia Fu; Ibrahim Qaddoumi; Célia Antoneli; Carlos Leal-Leal; Tarun Sharma; Margarita Barnoya; Sidnei Epelman; Louis Pizzarello; Javier R Kane; Ray Barfield; Thomas E Merchant; Leslie L Robison; A Linn Murphree; Patricia Chevez-Barrios; Michael A Dyer; Joan O'Brien; Raul C Ribeiro; John Hungerford; Eugene M Helveston; Barrett G Haik; Judith Wilimas Journal: Pediatrics Date: 2008-09 Impact factor: 7.124
Authors: Gail M Seigel; Abigail S Hackam; Arupa Ganguly; Lorrie M Mandell; Federico Gonzalez-Fernandez Journal: Mol Vis Date: 2007-06-08 Impact factor: 2.367
Authors: T Abruzzo; K Abraham; K B Karani; J I Geller; S Vadivelu; J M Racadio; B Zhang; Z M Correa Journal: AJNR Am J Neuroradiol Date: 2020-12-24 Impact factor: 3.825